Literature DB >> 20634070

Fluorine-18 labeled galactosylated chitosan for asialoglycoprotein-receptor-mediated hepatocyte imaging.

Wenjiang Yang1, Tiantian Mou, Wenyan Guo, Huihui Jing, Cheng Peng, Xianzhong Zhang, Yunchuan Ma, Boli Liu.   

Abstract

Galactosylated chitosan (GC) was prepared by reacting lactobionic acid with water-soluble chitosan. GC was labeled with fluorine-18 by conjugation with N-succinimidyl-4-(18)F-fluorobenzoate ([(18)F]SFB) under a slightly basic condition. After rapid purification with HiTrap desalting column, [(18)F]FB-GC was obtained with high radiochemical purity (>97%) determined by radio-HPLC. The total reaction time for [(18)F]FB-GC was about 150 min. Typical decay-corrected radiochemical yield was about 4-8%. Ex vivo biodistribution in normal mice showed that [(18)F]FB-GC had moderate activity accumulation in liver with very good retention (11.13+/-1.63, 10.97+/-1.90 and 10.77+/-0.95%ID/g at 10, 60, 120 min after injection, respectively). The other tissues except kidney showed relative low radioactivity accumulation. The high liver/background ratio affords promising biological properties to get clear images. The specific binding of this radiotracer to the ASGP receptor was confirmed by blocking experiment in mice. Compared with the non-blocking group the hepatic uptake of [(18)F]FB-GC significantly declined in all selected time points. The better liver retention properties of [(18)F]FB-GC than that of albumin based imaging agents may improve imaging quality and simplify pharmacokinetic model of liver function in the future application with PET imaging. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634070     DOI: 10.1016/j.bmcl.2010.06.106

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Authors:  Ming-Rong Cheng; Qing Li; Tao Wan; Bing He; Jiang Han; Hou-Xiang Chen; Feng-Xiao Yang; Wei Wang; Hong-Zhi Xu; Tao Ye; Bing-Bing Zha
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

2.  In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.

Authors:  Can Huang; Na-Mei Li; Pei Gao; Sa Yang; Qian Ning; Wen Huang; Zhi-Ping Li; Peng-Ju Ye; Li Xiang; Dong-Xiu He; Xiang-Wen Tan; Cui-Yun Yu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.

Authors:  Mingrong Cheng; Xiaoyan Gao; Yong Wang; Houxiang Chen; Bing He; Yingchun Li; Jiang Han; Zhiping Zhang
Journal:  Int J Nanomedicine       Date:  2013-11-06

4.  A new technique for the radiolabelling of mixed leukocytes with zirconium-89 for inflammation imaging with positron emission tomography.

Authors:  M Fairclough; C Prenant; B Ellis; H Boutin; A McMahon; G Brown; P Locatelli; A K P Jones
Journal:  J Labelled Comp Radiopharm       Date:  2016-04-08       Impact factor: 1.921

5.  A Novel Copolymer-Based Functional SPECT/MR Imaging Agent for Asialoglycoprotein Receptor Targeting.

Authors:  Pu Zhang; Zhide Guo; Deliang Zhang; Chang Liu; Guibing Chen; Rongqiang Zhuang; Manli Song; Hua Wu; Xianzhong Zhang
Journal:  Mol Imaging       Date:  2016-12-09       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.